Product Schedule A — Collateral Advisor
Product Schedule A v1.3.3
MARKETINGSENSE
PRODUCT SCHEDULE A
Collateral Advisor, a GrowthMind product operated by ImpactPlus Ventures LLP
Effective Date: 14 May 2026 | Version: 1.3.3
This Product Schedule forms part of and is subject to the MarketingSense Master Services Agreement (MSA). Terms defined in the MSA have the same meaning in this Schedule. In case of conflict between this Schedule and the MSA, this Schedule prevails for matters specific to Collateral Advisor.
1. SERVICE DESCRIPTION
1.1 About Collateral Advisor
Collateral Advisor is an AI-powered pre-MLR (Medical, Legal, Regulatory) advisory tool that helps pharmaceutical marketing teams create more effective collaterals by reviewing them across five critical dimensions simultaneously before they reach the MLR review stage.
Core Value Proposition: An effective collateral does more than pass MLR review. It engages the doctor, presents data credibly, delivers a clear message, and supports the conversation your field force wants to have. It generates incremental value for your brand with every use.
1.2 The Five Dimensions of Review
Creating collaterals that truly work requires getting multiple dimensions right simultaneously:
Medical Accuracy, so doctors trust your data and your corporate reputation is protected
Regulatory Readiness, to reduce compliance risk and avoid approval delays
Visual Design, so doctors engage and find the material relevant
Clear Messaging, so your key message lands and is remembered
Proper Structure, so information flows and attention is maintained
When any of these dimensions fall short, you are not getting the full return on your marketing collateral investment, and most importantly, your field force time and energy investment.
1.3 Five AI Expert Modules
Each reviewer focuses on a specific dimension. Together, they help identify potential issues and improvement opportunities:
1. Medical Reviewer
Reviews scientific claims and evidence alignment:
Examines clinical claims (efficacy, safety, dosing) for scientific accuracy concerns
Checks if citations are present and appear to support the claims
Generates PubMed search queries to help verify claims against published literature
2. Compliance Reviewer
Flags potential regulatory concerns for MLR attention:
Scans against UCPMP 2024, D&C Act 1940, DMRA 1954, ASCI Code, CCPA Guidelines
Identifies potentially prohibited terms with context consideration
Checks for required elements based on collateral type and drug schedule
3. Visual Design Reviewer
Examines images and visual elements:
Reviews medical illustrations and diagrams for accuracy concerns
Checks if visuals align with and support the text message
Flags cultural sensitivity considerations for Indian market
Identifies potential issues with graphs and charts
4. Copywriting Reviewer
Evaluates messaging clarity and suggests improvements:
Assesses message clarity and audience appropriateness
Reviews headline impact and call-to-action effectiveness
Identifies grammar, spelling, and punctuation errors
Provides alternative text suggestions for flagged issues
5. Best Practices Reviewer
Reviews structure and provides educational guidance:
Examines information flow and section ordering
Checks content density and readability for target audience
Reviews data presentation in charts and tables
Provides educational context explaining why best practices matter
1.4 Built-In Knowledge Base
The Service includes built-in expertise across five areas:
Indian Pharmaceutical Regulations: UCPMP 2024, Drugs & Cosmetics Act 1940, DMRA 1954, ASCI Code, CCPA Guidelines, CDSCO circulars
Collateral Frameworks: Industry-standard structures for different collateral types
Visual Design Principles: Medical illustration standards, cultural sensitivity, data visualization best practices
Copywriting Best Practices: Pharmaceutical messaging guidelines, clarity standards, persuasion principles
Content Structure Guidelines: Information flow, hierarchy, and attention management
1.5 Supported Collateral Types
The Service works across all major pharmaceutical marketing collateral types:
Doctor-Facing Detailing Materials:
Visual Aids
Leave Behind Literature (LBL)
Detail Aids
Reminder Cards
Division/Portfolio Reminder Cards
Physician Sample Pack (design and marketing content)
Print & Outdoor:
Print Advertisements
In-Clinic Posters
Banners (Print)
Digital Materials:
Digital Banners
WhatsApp Messages (Text, PDF, Static Images)
SMS Content
Conference & Events:
Conference Posters
Conference Standees
Conference Stall Materials
CME Invitations
Scientific & Reference:
Product Monographs
Scientific Article Folders
Patient Materials:
Patient Brochures
Disease Awareness Materials
1.6 What the Service Delivers
1. More Effective Collaterals in the Field
Stronger headlines and clearer messaging that doctors remember
Culturally appropriate visuals that resonate with Indian doctors
Optimized information flow that maintains attention
Better collateral, better conversations, better outcomes for your brand
2. Cleaner Submissions to MLR
Identify potential issues before materials reach MLR
Catch missing elements and possible regulatory concerns early
Reduce revision cycles and avoid post-printing discoveries
Faster time to field, more time for your collateral to work
3. A Team That Learns While It Works
Every report includes educational feedback. WHY something was flagged and HOW to address it:
Team members learn what makes collaterals effective through daily usage
Specific suggestions they can immediately consider
Over time, better first drafts equal increased ROI on field force efforts
1.7 Intended Users
The Service is designed for:
Pharmaceutical companies and their marketing, medical affairs, and regulatory teams
Nutraceutical, AYUSH, medical device, and cosmetic companies
Healthcare and life sciences organizations
Medical communication and advertising agencies serving pharmaceutical clients
Professionals involved in pharmaceutical marketing, regulatory affairs, and MLR review
2. PRODUCT-SPECIFIC DEFINITIONS
In addition to the definitions in the MSA, the following definitions apply to this Product Schedule:
"AI Output"
means any assessment report, risk assessment, compliance check, recommendation, or other result generated by the Service's AI expert modules (Medical Reviewer, Compliance Reviewer, Visual Design Reviewer, Copywriting Reviewer, Best Practices Reviewer).
"Collateral" or "Content"
means any pharmaceutical marketing material uploaded to the Service for assessment, including visual aids, leave-behinds, detail aids, reminder cards, product monographs, digital assets, emailers, conference posters, patient brochures, and other promotional materials.
"MLR"
means Medical, Legal, and Regulatory review, the standard industry process for approving pharmaceutical promotional materials.
"Regulatory Knowledge Base"
means the Service's curated database of Indian pharmaceutical regulations, prohibited terms, required elements, DMRA disease lists, collateral standards, and compliance guidelines.
"Expert Assessment Unit" or "EAU"
means the unit of usage purchased under your subscription plan that is consumed when Collaterals are processed through the Service. 1 EAU = 1 page assessed by all 5 AI reviewer modules.
"Assessment Report"
means the structured AI-generated assessment of your Collateral, including expert-wise findings across all five dimensions, risk scores, compliance flags, improvement recommendations, and educational guidance.
"Trial EAU"
means a unit of free trial usage made available to a trial user as described in Section 5A.
"Accessing the Service"
means logging into the MarketingSense Platform with valid credentials, or any post-login activity within the Platform, including uploading collateral, generating Assessment Reports, viewing AI Outputs, managing users, or consuming EAUs. For the avoidance of doubt, merely visiting the public marketingsense.in website does not constitute "accessing the Service" for the purposes of this Schedule or the MSA.
3. CRITICAL ADVISORY DISCLAIMER
HOW IT WORKS: The Service flags potential issues and provides recommendations. Your MLR team reviews the improved material and makes the final approval decision. We help you prepare better. Your MLR team decides what goes to field.
YOU EXPRESSLY ACKNOWLEDGE AND AGREE THAT:
(a) The Service provides PRE-MLR READINESS ASSESSMENTS FOR ADVISORY PURPOSES ONLY;
(b) The Service DOES NOT provide compliance certification, regulatory approval, or replace your internal MLR review process;
(c) ALL Assessment Reports and AI Outputs REQUIRE REVIEW AND APPROVAL by your qualified Medical, Legal, and Regulatory (MLR) teams before use;
(d) Service outputs shall NOT be construed as medical advice, legal counsel, regulatory guidance, or formal compliance certification;
(e) YOU bear FULL AND EXCLUSIVE responsibility for all final decisions regarding your pharmaceutical marketing materials;
(f) Service outputs are NOT suitable for direct use in regulatory filings, promotional materials, or doctor-facing communications without independent professional validation by qualified experts.
4. SERVICE LIMITATIONS
4.1 AI Model Limitations
You acknowledge and accept the following limitations:
AI models are trained on diverse datasets and may reflect limitations, biases, or inaccuracies;
AI outputs may occasionally produce incorrect, incomplete, or inconsistent results;
AI model updates may result in different outputs for similar inputs over time;
The Service flags potential issues for consideration. It does not make final decisions. Your MLR team may determine a flagged item is acceptable in context.
4.2 Regulatory Knowledge Base Limitations
The Regulatory Knowledge Base may not cover all evolving, highly specialized, or recently enacted pharmaceutical regulations;
Regulatory interpretations may vary and the Service reflects our understanding, not official regulatory positions;
Knowledge base updates occur periodically and may not reflect real-time regulatory changes;
State-specific regulations, international guidelines, or niche therapeutic area requirements may not be fully covered.
We make no warranties regarding the accuracy, completeness, timeliness, or fitness for purpose of any AI Output or Assessment Report. You use all outputs at your own risk and discretion.
5. EAU-BASED USAGE MODEL
5.1 EAU System
The Service operates on an EAU-based usage model:
EAU Consumption: 1 EAU = 1 page. All 5 AI reviewer modules examine every page, no extra charge. A 12-page visual aid uses 12 EAUs.
No User Seat Limits: Your subscription does not limit the number of Authorized Users; you may add unlimited users from your Organization.
EAU Allocation: Your subscription includes a defined number of EAUs as specified in your chosen plan.
Cumulative Usage: All usage by all Authorized Users under your subscription is cumulative and deducted from the Account Administrator's EAU pool.
EAU Tracking: Real-time EAU balance is visible in the Account Administrator's dashboard.
Additional EAUs: Top-up packs are available for existing subscribers who need more EAUs.
5.2 EAU Expiration & Rollover
Active Subscription: EAUs remain valid while your subscription is active.
Rollover on Renewal: When you renew, up to 25% of your plan's quarterly allocation may roll over to the next quarter. Rollover caps: Growth Plan, maximum 50 EAUs; Scale Plan, maximum 200 EAUs.
Post-Subscription Grace: If you do not renew, unused EAUs remain available for 90 days after subscription end. After the 90-day grace period, remaining EAUs expire.
Top-Up Expiry: Top-up EAUs are valid for 90 days from purchase date, regardless of subscription status.
Consumption Order (FIFO): When multiple EAU pools exist (Pilot, Trial, Top-up, Subscription), the system consumes EAUs in order of earliest expiry first.
5.3 EAU Refund Policy
EAUs are non-refundable once added to your account, except as provided in the MSA refund policy. Unused EAUs at the end of your subscription period are subject to the expiration policy above. Trial EAUs are non-refundable in any circumstance.
5A. FREE TRIAL PROVISIONS
5A.1 Trial Allocation
The free trial of Collateral Advisor is a promotional offering provided at ImpactPlus's sole discretion. ImpactPlus may make available a free trial consisting of an allocation of Trial EAUs per email address per calendar month, the size and frequency of which shall be determined by ImpactPlus at its sole discretion. The free trial is not a vested right and ImpactPlus may modify, suspend, or withdraw the trial offering at any time. Trial EAUs do not roll over, are not refundable in any form, and are not exchangeable for paid credits.
5A.2 Application of Terms
Trial users are bound by all provisions of this Product Schedule A and the Master Services Agreement, save where a provision is expressly stated to apply only to paid subscribers. For the avoidance of doubt, Section 6 (Competitor Restriction), Section 7 (Product-Specific Use Restrictions), and Section 8 (Your Compliance Responsibilities) apply with full force to trial users.
5A.3 Single-Account Rule
A natural person or an Organization may register for the free trial through one email address only, save where ImpactPlus has expressly authorised an agency-style trial in writing under Section 5A.4. Creation of multiple trial accounts by the same individual or Organization, including through use of secondary email addresses, alias addresses, or addresses belonging to other persons, constitutes a material breach of these terms.
5A.4 Credential Sharing and Agency Trials
Trial credentials may not be shared with any person other than the registered trial user. Group access, agency-style access, or any other form of multi-user trial access is prohibited, save where ImpactPlus has expressly authorised such access in writing in advance, in which case the terms of that written authorisation shall govern the scope and duration of the agency-style trial. Trial credentials may not be shared, sub-licensed, or transferred to any third party in any other circumstances.
5A.5 No Automated Access
Trial users shall not access the Service through any automated means, including scripts, bots, headless browsers, or programmatic interfaces, save where such access has been expressly authorised in writing by ImpactPlus.
5A.6 Output Use Restrictions
Trial Assessment Reports and AI Outputs are provided solely to enable the trial user to evaluate the Service. Trial outputs shall not be: (a) distributed or republished outside the trial user's Organization; (b) used as the operational basis for finalising, approving, or releasing pharmaceutical promotional collateral that will be deployed in the market or shared with doctors; (c) submitted in any external regulatory, compliance, or commercial process; or (d) referenced in any external communication outside the trial user's Organization. For the avoidance of doubt, internal use of trial outputs by the trial user for the purpose of evaluating whether to subscribe to a paid plan is permitted and is the intended use of the trial.
5A.7 No Substitute for Qualified Review
Trial outputs are advisory pre-MLR readiness assessments and do not constitute compliance certification or regulatory clearance. Trial users acknowledge that no decision on promotional collateral should be made on the basis of a trial Assessment Report alone.
5A.8 Output Watermarking
Every trial Assessment Report and AI Output carries a visible watermark identifying it as a trial-generated output. Removal, obscuring, or alteration of this watermark constitutes a material breach of these terms.
5A.9 Termination of Trial Access
ImpactPlus may suspend or terminate trial access immediately, with or without notice and at its sole discretion, for any breach of these provisions or the Master Services Agreement, or for any reason ImpactPlus considers reasonable in the circumstances. No refund or credit shall be payable on termination of trial access. Termination of trial access does not waive ImpactPlus's right to pursue any other remedy available at law for breach of these provisions.
6. COMPETITOR RESTRICTION
IMPORTANT RESTRICTION: You shall not access or use MarketingSense if you are employed by, contracted with, or acting on behalf of any entity that develops, markets, or operates services that compete with the Platform, including pre-MLR assessment tools, pharmaceutical compliance platforms, or AI-powered pharma marketing collateral advisory services.
This restriction applies to:
Direct competitors offering similar pre-MLR assessment or pharma collateral advisory services
Companies developing competing AI-powered pharmaceutical marketing tools
Consultants or contractors engaged by such competing entities
Any person acting on behalf of or providing information to such competitors
Violation of this restriction constitutes a material breach and grounds for immediate termination, with no refund or credit payable.
7. PRODUCT-SPECIFIC USE RESTRICTIONS
In addition to the use restrictions in the MSA, the following restrictions apply to this Service:
7.1 Pharmaceutical & Regulatory Restrictions
Do not create promotional content that violates UCPMP guidelines, makes unsubstantiated therapeutic claims, or promotes off-label drug use
Do not upload content containing patient-identifiable clinical data, individual health records, or personal health information (the Service assesses marketing collaterals, not clinical documents)
Do not use Service outputs as substitutes for regulatory submissions or official compliance certifications
Do not input false, misleading, or deliberately corrupted data to manipulate assessment results
7.2 Content Restrictions
Upload only pharmaceutical marketing collaterals intended for the Indian market
Ensure all uploaded content complies with applicable intellectual property laws
Do not upload content containing trade secrets of third parties obtained without authorization
7.3 Output Usage Restrictions
Assessment Reports are for your Organization's internal use only
Do not share Assessment Reports with third parties for purposes of competitive analysis
Do not use AI Outputs to train competing AI models or develop competing services
Do not reverse-engineer the Service's methodologies, scoring algorithms, or knowledge base from outputs
8. YOUR COMPLIANCE RESPONSIBILITIES
8.1 Pharmaceutical Regulatory Compliance
You bear FULL AND EXCLUSIVE responsibility for ensuring that all your Collaterals, marketing decisions, and use of Service outputs comply with all Applicable Laws, including:
Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024
Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954
Drugs and Cosmetics Act, 1940 and Rules
National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2023 (as in force from time to time)
CDSCO guidelines and circulars
ASCI Code and CCPA Guidelines
Digital Personal Data Protection Act, 2023
8.2 Disclosure of Applicable Standards
You shall inform us of any specific regulatory, statutory, or industry-specific restrictions that may apply to your particular products, therapeutic areas, or marketing activities. We shall be entitled to rely on your representations regarding permissible claims, advertising channels, and compliance norms.
8.3 Content Validation Requirement
You shall exercise independent professional judgment, conduct thorough review by your qualified Medical, Legal, and Regulatory experts, and obtain appropriate internal approvals before using any Service output for external communications, promotional materials, or business decisions. The Service is a tool to assist your MLR process, not replace it.
8.4 Usage Documentation
You shall maintain reasonable records of Service usage, including the business purpose for assessments performed and the review/validation process followed before using outputs. Such records shall be available for our review upon reasonable request in connection with compliance audits.
8.5 User Training
You shall ensure all Authorized Users receive adequate training on: (a) Service acceptable use policies; (b) AI output limitations and validation requirements; (c) pharmaceutical regulatory compliance obligations; and (d) confidentiality and data protection requirements. We provide training materials and guidance videos through the Platform.
8.6 Incident Reporting
You shall promptly report to us any: (a) suspected security breach or data exposure; (b) Service misuse by your users; (c) regulatory inquiries related to Service outputs; or (d) intellectual property concerns. Reports should be sent to growth@impactplus.co.in.
9. PRODUCT-SPECIFIC DISCLAIMERS
9.1 Pharmaceutical Disclaimer
The Service does not provide medical, regulatory, or therapeutic advice. All content, tools, and outputs are for internal assessment and decision-support purposes only. Outputs shall not be construed as clinical guidance, regulatory certification, or assurance of compliance or market outcomes.
9.2 Data & Performance Disclaimer
All insights and outputs depend on the Collaterals you provide and our Regulatory Knowledge Base. We do not guarantee accuracy, completeness, or any specific business, regulatory, or operational results from using the Service.
9.3 Technology Disclaimer
Service availability and performance may be impacted by evolving technology, AI model updates, third-party systems, or external events. We disclaim responsibility for disruptions due to force majeure, internet connectivity issues, or changes in third-party APIs.
9.4 No Guarantee of MLR Approval
The Service provides advisory pre-MLR readiness assessments. We do not guarantee that collaterals assessed through the Service will be approved by your MLR team, regulatory authorities, or any third party.
10. PRODUCT-SPECIFIC INDEMNIFICATION
In addition to the indemnification obligations in the MSA, you agree to indemnify ImpactPlus from claims arising from:
Violations of UCPMP, DMRA, DPDP Act, CDSCO guidelines, or other pharmaceutical regulations due to your marketing materials or decisions;
Your use of Service outputs contrary to the disclaimers in this Schedule or without appropriate MLR validation;
Your failure to validate AI Outputs through qualified professionals before business use;
Regulatory penalties arising from your failure to disclose applicable compliance requirements;
Third-party claims arising from collaterals that you created, modified, or distributed after using the Service.
11. SUBSCRIPTION PLANS AND PRICING
The Service is offered in the following subscription tiers:
11.1 Pilot Program
90-Day Pilot, Rs 5,000 (excl. GST)
30 EAUs to evaluate the Service with your real collaterals
All 5 AI reviewer modules included
Detailed Assessment Reports with recommendations
Comprehensive onboarding (video tutorials + web app tour)
Full support: WhatsApp, email, online meeting
Pilot Credit Adjustment: If you subscribe within 90 days of your Pilot purchase, the full Rs 5,000 Pilot fee is adjusted against your subscription.
Pilot Cooldown: A minimum of 6 months must pass before purchasing a second Pilot.
11.2 Subscription Plans
Growth Plan, Rs 25,000/quarter (excl. GST)
For single divisions or small teams with regular advisory needs
200 EAUs per quarter
All 5 AI reviewer modules
Quarterly and Annual billing options
Up to 50 EAUs rollover on renewal (25% cap)
Scale Plan, Rs 76,000/quarter (excl. GST)
For multi-division organizations with high-volume requirements
800 EAUs per quarter
All 5 AI reviewer modules
Quarterly and Annual billing options
Up to 200 EAUs rollover on renewal (25% cap)
Enterprise
For large organizations with custom requirements
Custom EAU allocation
API access and dedicated point of contact
Contact us for enterprise pricing: growth@impactplus.co.in
Annual Billing Discount: Pay for 4 quarters upfront and save 15%.
11.3 Top-Up Packs
For existing subscribers who need additional EAUs:
Quick-Response: 20 EAUs, Rs 3,500 (Rate per EAU: Rs 175)
Campaign Booster: 50 EAUs, Rs 7,500 (Rate per EAU: Rs 150)
Enterprise Supplemental: 100 EAUs, Rs 12,000 (Rate per EAU: Rs 120)
All prices exclude GST (18%). Top-up EAUs are valid for 90 days from purchase.
If you consistently need more EAUs than your plan provides, upgrading to the next tier offers better value per EAU.
12. SERVICE UPDATES
We may update the Service from time to time to:
Improve AI model accuracy and performance
Update the Regulatory Knowledge Base with new regulations and guidelines
Add new features and capabilities
Enhance security and reliability
Support additional collateral types
Material changes affecting user workflows will be communicated in advance. AI model updates may result in different outputs for similar inputs; this is expected behavior as we continuously improve the Service.
13. TECHNICAL SPECIFICATIONS
13.1 Supported File Formats
PDF (single or multi-page)
PNG
JPG/JPEG
Maximum file size: 10MB
13.2 Processing Time
Processing time varies based on page count, content complexity, and the depth of analysis required. Most collaterals are processed within a few minutes.
13.3 Data Security
Data protection is fundamental to how we have built Collateral Advisor.
Security Measures:
Encryption: All data encrypted in transit (TLS) and at rest
India-Hosted: Data stored on secure servers within India
No AI Training: Your promotional materials are not used to train external AI models
Retention Policies: Data retention practices are set out in the MSA Section 11.6 (Data Retention Schedule) and the Privacy Policy Section 13 (Data Retention and Deletion). Retention follows a four-tier framework aligned with the DPDP Act 2023 and other applicable Indian laws.
Secure Infrastructure: Industry-standard security practices for cloud-hosted applications
Data Handling:
Your uploaded promotional materials and assessment reports are stored securely and used solely for providing the service you have subscribed to. We do not share your data with third parties except as required to deliver the service (such as cloud infrastructure providers who are bound by confidentiality obligations).
14. RELATIONSHIP WITH MSA AND AMENDMENTS
14.1 Relationship with MSA
This Product Schedule is incorporated into and forms part of the MarketingSense Master Services Agreement. By "accessing the Service" (as defined in Section 2) or subscribing to Collateral Advisor, you agree to both:
The MarketingSense Master Services Agreement (common terms for all Product Offerings)
This Product Schedule A: Collateral Advisor Terms
Acceptance occurs when you log into the Platform with valid credentials or otherwise undertake post-login activity within the Platform. Visiting the public marketingsense.in website does not by itself constitute acceptance of this Schedule or the MSA. The MSA contains important provisions regarding liability limitations, dispute resolution, and other legal terms that apply to your use of this Service.
14.2 Amendments to this Schedule
Amendments to this Schedule shall follow the two-tier amendment mechanism set out in Section 15.2 of the Master Services Agreement. Non-material amendments to this Schedule will be notified to the Account Administrator at least 30 days before taking effect, and continued use of the Service after the effective date constitutes acceptance. Material amendments affecting how your personal data is processed will require active in-platform re-acknowledgement before continued access to the Platform.
ACCEPTANCE
By "accessing the Service" (as defined in Section 2) or subscribing to Collateral Advisor, you acknowledge that:
You have read and understood this Product Schedule in its entirety;
You understand that the Service provides ADVISORY pre-MLR readiness assessments only;
You acknowledge that ALL Assessment Reports and AI Outputs require verification by your qualified MLR professionals before use;
You accept FULL RESPONSIBILITY for compliance with pharmaceutical regulations;
You understand the EAU-based usage model (1 EAU = 1 page) and that all user activity is cumulative under your subscription;
You confirm that you are not employed by, contracted with, or acting on behalf of any entity that competes with the Platform;
You agree to the terms of both this Product Schedule and the Master Services Agreement.
END OF PRODUCT SCHEDULE A
Collateral Advisor
MarketingSense is a GrowthMind product by ImpactPlus